Key facts
- This page summarizes Eric Karas's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Aug 2024, 18:51.
Eric Karas - 19 Aug 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- SPRY
- Reported as of
- 19 Aug 2024
- Net transaction value
- -$125,000
- SEC form
- 4
- Accepted by SEC
- 21 Aug 2024, 18:51:06 UTC
- Prior SEC filing
- 04 Jan 2024
- Next SEC filing
- 19 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathleen Scott, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Karas filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 21 Aug 2024.
Change
- Previous filing in this sequence was filed on 04 Jan 2024.
- Current net transaction value: -$125,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRY
transaction
Common Stock
Options Exercise
- Transaction value
- $15,000
- Shares
- +10,000
- Change %
- +176%
- Price
- $1.50
- Shares after
- 15,693
- Date
- 19 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
SPRY
transaction
Common Stock
Sale
- Transaction value
- $140,000
- Shares
- -10,000
- Change %
- -64%
- Price
- $14.00
- Shares after
- 5,693
- Date
- 19 Aug 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRY
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -10,000
- Change %
- -1.6%
- Price
- $0.000000
- Shares after
- 604,588
- Date
- 19 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $1.50
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Includes 1,984 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023, 1,232 shares acquired under the ESPP on December 29, 2023 and 2,477 shares acquired under the ESPP on June 28, 2024.
Footnote F2
The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
Footnote F3
Immediately exercisable.